201 related articles for article (PubMed ID: 22316363)
21. Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic options.
Lazzari C; Spitaleri G; Catania C; Barberis M; Noberasco C; Santarpia M; Delmonte A; Toffalorio F; Conforti F; De Pas TM
Crit Rev Oncol Hematol; 2014 Mar; 89(3):358-65. PubMed ID: 24156959
[TBL] [Abstract][Full Text] [Related]
22. The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders.
Roskoski R
Expert Opin Drug Discov; 2013 Sep; 8(9):1165-79. PubMed ID: 23805942
[TBL] [Abstract][Full Text] [Related]
23. ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?
Girard N; Audigier-Valette C; Cortot AB; Mennecier B; Debieuvre D; Planchard D; Zalcman G; Moro-Sibilot D; Cadranel J; Barlési F
Expert Rev Anticancer Ther; 2015 Feb; 15(2):225-33. PubMed ID: 25413260
[TBL] [Abstract][Full Text] [Related]
24. Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer.
Kijima T; Takeuchi K; Tetsumoto S; Shimada K; Takahashi R; Hirata H; Nagatomo I; Hoshino S; Takeda Y; Kida H; Goya S; Tachibana I; Kawase I
Cancer Sci; 2011 Aug; 102(8):1602-4. PubMed ID: 21767331
[TBL] [Abstract][Full Text] [Related]
25. Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer.
Li S; Qi X; Huang Y; Liu D; Zhou F; Zhou C
Clin Lung Cancer; 2015 Mar; 16(2):86-91. PubMed ID: 25458559
[TBL] [Abstract][Full Text] [Related]
26. New targets in advanced NSCLC: EML4-ALK.
Crystal AS; Shaw AT
Clin Adv Hematol Oncol; 2011 Mar; 9(3):207-14. PubMed ID: 21475126
[TBL] [Abstract][Full Text] [Related]
27. Heart rate decrease during crizotinib treatment and potential correlation to clinical response.
Ou SH; Tong WP; Azada M; Siwak-Tapp C; Dy J; Stiber JA
Cancer; 2013 Jun; 119(11):1969-75. PubMed ID: 23505007
[TBL] [Abstract][Full Text] [Related]
28. Crizotinib.
Heigener DF; Reck M
Recent Results Cancer Res; 2014; 201():197-205. PubMed ID: 24756793
[TBL] [Abstract][Full Text] [Related]
29. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer.
Pailler E; Adam J; Barthélémy A; Oulhen M; Auger N; Valent A; Borget I; Planchard D; Taylor M; André F; Soria JC; Vielh P; Besse B; Farace F
J Clin Oncol; 2013 Jun; 31(18):2273-81. PubMed ID: 23669222
[TBL] [Abstract][Full Text] [Related]
30. [Crizotinib: At last in first-line treatment of advanced-stage ALK-rearranged non-small cell lung cancer].
Giroux Leprieur E; Wislez M
Bull Cancer; 2016 Feb; 103(2):125-6. PubMed ID: 26822904
[No Abstract] [Full Text] [Related]
31. Targeting anaplastic lymphoma kinase in lung cancer.
Shaw AT; Solomon B
Clin Cancer Res; 2011 Apr; 17(8):2081-6. PubMed ID: 21288922
[TBL] [Abstract][Full Text] [Related]
32. Targeted therapy for NSCLC: ALK inhibition.
Pearson R; Kolesar JM
J Oncol Pharm Pract; 2012 Jun; 18(2):271-4. PubMed ID: 21844131
[TBL] [Abstract][Full Text] [Related]
33. Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib?
Rolfo C; Passiglia F; Russo A; Pauwels P
Expert Opin Ther Targets; 2014 Sep; 18(9):983-5. PubMed ID: 24998601
[TBL] [Abstract][Full Text] [Related]
34. Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer.
Solomon B; Wilner KD; Shaw AT
Clin Pharmacol Ther; 2014 Jan; 95(1):15-23. PubMed ID: 24091716
[TBL] [Abstract][Full Text] [Related]
35. The efficacy of crizotinib in patients with ALK-positive nonsmall cell lung cancer.
Pender A; Popat S
Ther Adv Respir Dis; 2015 Jun; 9(3):97-104. PubMed ID: 25801645
[TBL] [Abstract][Full Text] [Related]
36. Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient.
Lu S; Azada MC; Ou SH
Lung Cancer; 2015 Feb; 87(2):207-9. PubMed ID: 25558789
[TBL] [Abstract][Full Text] [Related]
37. Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.
Huang D; Kim DW; Kotsakis A; Deng S; Lira P; Ho SN; Lee NV; Vizcarra P; Cao JQ; Christensen JG; Kim TM; Sun JM; Ahn JS; Ahn MJ; Park K; Mao M
Genomics; 2013 Sep; 102(3):157-62. PubMed ID: 23434628
[TBL] [Abstract][Full Text] [Related]
38. Crizotinib.
Heigener DF; Reck M
Recent Results Cancer Res; 2018; 211():57-65. PubMed ID: 30069759
[TBL] [Abstract][Full Text] [Related]
39. Crizotinib for the treatment of non-small-cell lung cancer.
Timm A; Kolesar JM
Am J Health Syst Pharm; 2013 Jun; 70(11):943-7. PubMed ID: 23686600
[TBL] [Abstract][Full Text] [Related]
40. Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target.
Gandhi L; Jänne PA
Clin Cancer Res; 2012 Jul; 18(14):3737-42. PubMed ID: 22547770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]